J.P. Morgan Lowers PT on Clorox Company from $140 to $133, Keeps Hold Rating

The Clorox Company (NYSE:CLX) is one of the top stocks that Grok recommended. On August 1, J.P. Morgan lowered its price target on The Clorox Company (NYSE:CLX) from $140 to $133, keeping its Hold rating on the stock.

Andrea Faria Teixeira from J.P. Morgan reduced the price target on CLX following Q4 FY2025 results. The company posted adjusted earnings per share of $2.87, exceeding estimates by $0.66 per share. The revenue reached almost $2 billion, surpassing the estimated $1.94 billion. The sales were mainly driven by the increased ERP shipments.

Teixeira slightly lowered the price target on CLX as the company suffered challenges from the divestiture of its Better Health Vitamins, Minerals, and Supplements business and an unfavourable price mix. The analyst holds the rating while remaining cautious as the company anticipates a transitory impact on sales and earnings in FY2026 due to the ERP system transition. Clorox projects earnings per share between $5.95-$6.30 in FY2026, which is just in line with the average consensus estimate of $6.20.

The Clorox Company (NYSE:CLX) is a multinational manufacturer and marketer of consumer and professional products. The company operates through four segments, including Health and Wellness, Household, Lifestyle, and International.

While we acknowledge the potential of CLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.